GLP-1 weight-loss drugs might be providing a quick fix to a growing number of users but there are many unknowns as to the real or potential hit on packaged foods manufacturers in both the short and ...
The early stages of any new, clinically impactful drug put pressure on benefit leaders. While research evolves at a pace that keeps health care professionals on their toes, benefit leaders must make ...
Can the new GLP-1s help prevent cancer before it starts by tackling obesity and all the dysfunctional metabolic pathways that ...
Glucagon-like peptide-1, or “GLP-1” drugs, such as Ozempic® and Mounjaro®, have exploded in popularity in the United States for weight management and the treatment of obesity. However, GLP-1 drugs ...
GLP-1 drugs like Ozempic are transforming weight loss and diabetes management. But no good deed goes unpunished, and the manufacturers of these medicines now face a wave of lawsuits, with plaintiffs ...
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...
NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is ...
We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a growing swarm of lawsuits threatens to upend the billion-dollar industry. Are ...
New research reveals how food and beverage brands can lead innovation for millions facing sensory and nutritional challenges “IFF is empowering our customers to lead the next wave of food and beverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results